Natera, Inc. $NTRA Shares Acquired by Focus Partners Advisor Solutions LLC

Key Points

• Focus Partners Advisor Solutions LLC significantly increased its stake in Natera, Inc. by 144.2%, amassing a total of 3,504 shares valued at approximately $496,000.
• Natera reported a 32.2% year-over-year revenue increase, generating $546.60 million, but missed earnings estimates with a loss of ($0.74) EPS.
• Institutional investors own 99.90% of Natera's stock, with numerous firms acquiring new stakes or increasing their existing positions during the first quarter.

Focus Partners Advisor Solutions LLC increased its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 144.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,504 shares of the medical research company's stock after purchasing an additional 2,069 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Natera were worth $496,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. LRI Investments LLC acquired a new stake in Natera in the fourth quarter worth about $29,000. Bank of Jackson Hole Trust acquired a new stake in Natera in the first quarter worth about $29,000. Rakuten Securities Inc. raised its position in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC bought a new stake in Natera in the first quarter worth about $32,000. Finally, TCTC Holdings LLC raised its position in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after acquiring an additional 124 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Trading Up 0.9%

NASDAQ NTRA opened at $168.02 on Friday. The stock's 50-day moving average price is $154.35 and its two-hundred day moving average price is $153.91. The company has a market cap of $23.06 billion, a PE ratio of -87.97 and a beta of 1.68. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's quarterly revenue was up 32.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Activity

In other Natera news, Director Gail Boxer Marcus sold 2,496 shares of Natera stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $133.17, for a total transaction of $332,392.32. Following the transaction, the director owned 5,763 shares of the company's stock, valued at $767,458.71. The trade was a 30.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,807 shares of Natera stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $132.88, for a total value of $771,634.16. Following the transaction, the chief executive officer directly owned 163,593 shares in the company, valued at approximately $21,738,237.84. This trade represents a 3.43% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 55,344 shares of company stock worth $8,271,610. 5.63% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have commented on NTRA shares. Cowen reiterated a "buy" rating on shares of Natera in a research report on Friday, August 8th. Morgan Stanley reiterated an "overweight" rating and issued a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. Barclays reiterated an "overweight" rating and issued a $210.00 price target (up from $190.00) on shares of Natera in a research report on Friday, August 8th. UBS Group boosted their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Finally, Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research report on Monday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $194.00.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.